तुलना करने के लिए मीट्रिक्स | 365270 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध365270पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −23.4x | −7.5x | −0.2x | |
PEG अनुपात | −0.32 | −0.09 | 0.00 | |
क़ीमत/बुक | 3.8x | 2.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 21.5x | 7.2x | 2.8x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 64.7% | 62.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | 10.3% | 8.0% | अनलॉक करें |
curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company’s products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- ß/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combining Tie2 agonist and anti-VEGF functions for the treatment of wAMD. It also develops MT-105 for the treatment of irritable bowel diseases; MT-201, a non-bleeding anti-thrombotic antibody targeting PD-X; MT-202, a dual-mechanism therapy combining PD-X inhibition and Tie2 agonism for the treatment of acute ischemic stroke and heart failure with preserved ejection fraction; CU71, a next-generation neurovascular stabilizer for the treatment of alzheimer's disease; and CP01-R01, a first oral endothelial stabilizer–based candidate for companion animal CKD therapy. In addition, the company develops SOLVADYS, proprietary oral small-molecule platform for the treatment of endothelial dysfunction; and EAGLES, a flagship platform of Maptics for next-generation biologics. curacle co.,ltd. was incorporated in 2016 and is headquartered in Seoul, South Korea.